Recent advances in molecular technologies have facilitated breast cancer research, allowing researchers and physicians to use biomarkers expressed by cancerous cells to categorize this pathology into four distinct groups—luminal A, luminal B, HER2-positive and TNBC. Here, ERBB2 is linked to breast carcinoma.